GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kangstem Biotech Co Ltd (XKRX:217730) » Definitions » Research & Development

Kangstem Biotech Co (XKRX:217730) Research & Development : ₩12,878 Mil (TTM As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Kangstem Biotech Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Kangstem Biotech Co's Research & Development for the three months ended in Mar. 2025 was ₩3,231 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was ₩12,878 Mil.


Kangstem Biotech Co Research & Development Historical Data

The historical data trend for Kangstem Biotech Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kangstem Biotech Co Research & Development Chart

Kangstem Biotech Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12,638.60 14,652.93 14,220.04 14,030.18 12,143.21

Kangstem Biotech Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,496.90 3,594.73 2,863.71 3,188.06 3,231.12

Kangstem Biotech Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩12,878 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kangstem Biotech Co  (XKRX:217730) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Kangstem Biotech Co Research & Development Related Terms

Thank you for viewing the detailed overview of Kangstem Biotech Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Kangstem Biotech Co Business Description

Traded in Other Exchanges
N/A
Address
512 Teheran-ro, Gangnam-gu, 17th Floor, Sinan Building, Seoul, KOR
Kangstem Biotech Co Ltd develops technology to isolate the non-hematological system stem cell with conversion and purity from the cord blood and to culture large quantity. Its Furestem therapies include Furestem-AD, Furestem-RA and Furestem-CD. Its businesses include cord blood-derived stem cell therapy business; cord blood-derived stem cell conditioned media business; and stem cell culture media business.

Kangstem Biotech Co Headlines

No Headlines